Hinova Pharmaceuticals’ HC-1119 NDA Accepted for Review by NMPA
Chengdu-based biotech Hinova Pharmaceuticals Inc. (SHA: 688302) has announced that the New Drug Application (NDA)...
Drug
Boehringer Ingelheim Initiates Phase III FIBRONEER Studies for PDE4B Inhibitor BI 1015550
German pharmaceutical giant Boehringer Ingelheim (BI) has announced the first patient enrollments in the Phase...
Advenchen Lab’s AL8326 and Hengrui’s SHR-A1811 Receive Breakthrough Therapy Designations
The Center for Drug Evaluation (CDE) website indicates that Advenchen Lab’s AL8326 and Hengrui Pharmaceuticals’...
Biokin’s BL-B01D1 Receives NMPA Approval for Phase II Solid Tumor Study
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has received approval...
Junshi Biosciences’ JS010 Receives NMPA Approval for Migraine Clinical Trials
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that it has received clinical trial...
Immunotech Biopharm’s CAR-T-19-D2 Receives NMPA Approval for DLBCL Clinical Trial
China-based chimeric antigen receptor T-cell (CAR-T) specialist Immunotech Biopharm Ltd (HKG: 6978) has announced that...
Reistone Biopharma’s Ivarmacitinib Shows Positive Results in Phase III QUARTZ3 Study
Reistone Biopharma Co., Ltd, incubated by Hengrui Pharmaceuticals (SHA: 600276) with USD 100 million in...
Yifan Pharmaceutical’s F-652 Cleared for Phase II Trial in Alcoholic Hepatitis
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) has announced that its subsidiary Evive Biotech Ltd’s...
Yiling Pharmaceutical’s BIO-008 Receives NMPA Approval for Clinical Trials
China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that it has received clinical trial...
Hengrui Pharmaceuticals’ SHR8028 Receives NMPA Review for Dry Eye Treatment
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that a market approval filing...
Jiangsu Recbio’s ReCOV Vaccine Receives Emergency Use Authorization in Mongolia
China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) has announced that it has...
Luye Pharma’s BA1102 Biosimilar to Xgeva Accepted for CDE Review
China-based Luye Pharma Group (HKG: 2186) has announced that a market approval filing for its...
Bayer’s Nubeqa Receives Additional NMPA Approval for mHSPC Treatment-Fineline Info & Tech
German pharmaceutical giant Bayer AG (ETR: BAYN) has announced that it has received another indication...
NMPA Denies Market Approval for Hengrui’s Plinabulin in Chemotherapy-Induced Neutropenia
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) announced in a stock exchange statement that the...
SciClone Pharmaceuticals’ Vaborem Approved for Phase III Clinical Trial in China
SciClone Pharmaceuticals Inc (HKG: 6600) has announced that a clinical trial filing for its Vaborem...
Janssen Withdraws Carvykti from UK Market Amid Manufacturing Concerns
US-based Janssen Pharmaceutical reportedly decided to withdraw Carvykti (ciltacabtagene autoleucel; cilta-cel) from the UK market...
Hainan Poly Pharm’s Generic Gadovist Receives FDA Approval for MRI Use
China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced that it has received marketing...
Jacobio Pharma’s JAB-24114 Receives CDE Approval for Phase I/IIa Clinical Study
China-based Jacobio Pharma (HKG: 1167) has announced that it has received approval from the Center...
Hengrui Pharmaceuticals’ Dexmedetomidine Nasal Spray Approved by NMPA
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received marketing...
Tot Biopharmaceutical Terminates Phase III Study for HER2-Targeted ADC TAA013
Tot Biopharmaceutical International Co., Ltd (HKG: 1875) has announced the termination of the Phase III...